Plain-English translation of NCT05930093 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a medication called LivPhcD capsules to see if it can help reduce excess fat in the liver. The study will compare different doses of this medication against a placebo (an inactive pill) in people who have been diagnosed with nonalcoholic fatty liver disease (NAFLD). Right now, there are no FDA-approved medications for this condition, so researchers are trying to find new treatment options.
Fatty liver disease affects about one in four people worldwide, and in some cases it can lead to serious liver damage like scarring or cirrhosis. While diet and exercise can help, most patients struggle to stick with these changes long-term, so doctors need medication options to help patients.
You likely qualify if…
You likely don't qualify if…
If you are selected, you will be randomly assigned to take either a placebo or one of three different doses of the medication—2, 4, or 6 capsules per day. You won't know which group you're in (this is called being 'blinded'). Throughout the study, you will have regular visits where doctors will check your liver health using imaging scans called Fibroscan and blood tests. The study will measure how well the medication reduces fat in your liver and monitor you for any side effects.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Taiwan